donepezil

Číslo: 6 / 2009 (Obsah)
Rubrika: Profily léčiv
Obor: Psychiatrie
Autoři: Doc. MUDr. Roman Jirák, CSc. 
Autoři - působiště: Psychiatrická klinika 1. LF UK, Praha
Citace: 1 AD 2000 Collaborative Group: Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomized, double-blind trial. Lancet 2004;363:2105–2115. 2 Bentue-Ferrer D, Tribut O, Polard E, et al. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003;17:947–63. 3 Black S, Román GC, Geldmacher DS, et al; Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323–32. 4 Black SE, Doody R, Li H, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007;69:459–68. 5 Beversdorf DK, Warner J, Davis R, et al. Donepezil in the treatment of dementia with Lewy bodies. Am J Geriat Psychiatry 2004;12:542–4. 6 Birks JS, Melzer D, Beppeu H. Donepezil for mild and moderate Alzheimer’s disease (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford, GB. 7 Bucay AH. Donepezil (aricept) as a treatment for anorexia nervosa: a very feasible therapeutic possibility. Exp Opin Invest Drugs 2009;18:569–71. 8 Cacabelos R. Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiatric Dis Treatment 2007;3:303–33. 9 Caltagirone C, Bianchetti A, Di Luca M, et al. Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics. Drugs Aging 2005;22(Suppl 1):1–26. 10 Cummings JL. Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2005;76:903–4. 11 Donepezil Monograph. Clinical Pharmacology (database on the internet). www.clinicalpharmacology.com. 12 Doody R, Correy-Bloom J, Zhang R, et al. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patiens with Alzheimer’s disease. Drugs Aging 2008;25:163–74. 13 Giacobini E. Cholinesterases and cholinesterase inhibitors. London: Martin Dunitz, 2000. 14 Goldsmith DR, Scott LJ. Donepezil: in vascular dementia. Drugs Aging 2003;20:1127–36. 15 Hanyu H, Shimizu T, Tanaka Y, et al. Regional cerebral blood flow patterns and response to donepezil treatment in patiens with Alzheimer’s disease. Dement Geriatr Cogn Disord 2003;15:177–82. 16 Christodolou C, Melville P, Scherl WF, et al. Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 2006;245:127–36. 17 Imamura K, Wada-Isoe K, Kowa H, et al. The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson’s disease dementia. Eurocase 2008;14:271–5. 18 Jacobson SA, Sabbagh MN. Donepezil: potential neuroprotective and disease-modifying effects. Exp Opin Drug Metab Toxicol 2008;4:1363–9. 19 Jirák R, Borzová C, Konrád J, et al. Demence. In: Raboch J, Anders M, Praško J, Hellerová P, eds. Psychiatrie. Doporučené postupy psychiatrické péče II. Praha: Infopharm, 2006:22–37. 20 Khateb A, Ammann J, Annoni J-M, et al. Cognition-enhancing effects of donepezil in traumatic brain injury. Eur Neurol 2005;54:39–45. 21 Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD004395.DOI: 10.1002/14651858.CD004395.pub2. 22 Maltz JS, Eberling JL, Jagust WJ, et al. Enhanced cutaneous vascular response in AD subjects under donepezil therapy. Neurobiol Aging 2004;25:475–81. 23 Marder K, Marder K. Donepezil in patiens with severe Alzheimer’s disease: double-blind parallel-group, placebo controlled study. Current Neurol Neurosci Reports 2006; 6:364–73. 24 Mendez MF, Zounesi FL, Perryman KM. Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999;11:268–70. 25 Nagy CF, Kumar D, Cullen EI, et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol 2004;58(s1):18–24. 26 NICE guideline: CG42 Dementia; http://guidance.nice.org.uk/ cg42/niceguidance/pdf/English (22. 4. 2009). 27 Niederhofer H, Niederhofer H. Donepezil also effective in the treatment of Tourette’s syndrome? Movement Disord 2006; 21:2027. 28 Peterson RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379–88. 29 Qizilbash N, Schneider,LS, Chui H, et al, eds. Evidence-based dementia practice. Oxford: Blackwell Science Ltd and Blackwell publishing company, 2003:428–46. 30 Reyes J, Vargas R, Kumar D, et al. Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. Br J Clin Pharmacol 2004;58(s1):9–17. 31 Roman GC, Wilkinson DG, Doody RS, et al. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. Dement Geriatr Cogn Disord 2005;20:338–44. 32 Švestka J. Nová psychofarmaka: Kognitivum donepezil. Psychiatrie 1999;3:36–44. 33 Tateno M, Kobayashi S, Utsomi K, et al. Quantitative analysis of the effects of donepezil on regional cerebral blood flow in Alzheimer’s disease by using an automated program, 3DSRT. 34 Van Dam D, Coen K, De Deyn P. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer’s disease. Psychopharmacology 2008; 197:37–43. 35 Varsaldi F, Miglio G, Gabriella Scordo M, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol 2006;62:721–6. 36 Wilkinson D, Doody R, Helme R, et al; Donepezil 308 Study Group: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61:479–86. 37 Winblad B, Wimo A, Engedal K, et al. 3-year study of donepezil therapy in Alzheimer’s disease: effects of early and continuous therapy. Dementia Geriatric Cognitive Disorders 2006;21:353–64. 38 Winblad B, Kilander L, Eriksson S, et al. Donepezil in patiens with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057–65. 39 Winblad B, Black SE, Homma A, et al. Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin 2009;25:2577–87. 40 Yasuki-Furukori N, Furukori H, Kaneda A, et al. The effects of Ginkgo biloba extracts on the pharmacodynamics of donepezil. J Clin Pharmacol 2004;44:538–42. 41 Yoshida T, H-Kawa S, Sawada S, et al. Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patiens with Alzheimer’s disease. Ann Nucl Med 2007;21:257–65.

Celý článek je dostupný jen pro předplatitele časopisu


Přihlášení

 

Předplatné

Více o předplatném

 
 
 
Jste odborný pracovník ve zdravotnictví?
Jsem odborníkem ve smyslu §2a Zákona č. 40/1995 Sb., o regulaci reklamy, ve znění pozdějších předpisů, čili jsem osobou oprávněnou předepisovat léčivé přípravky nebo osobou vydávat léčivé přípravky.

Potvrzuji, že jsem se seznámil/a s definicí odborník
dle zákona č. 40/1995 Sb.
Potvrzuji, že jsem se seznámil/a s riziky, jimž se jiná osoba než odborník vystavuje, vstoupí-li na stránky určené pro odborníky